Austin Aerts Sells 2,431 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 2,431 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $8.06, for a total transaction of $19,593.86. Following the transaction, the chief financial officer now directly owns 283,325 shares of the company’s stock, valued at $2,283,599.50. The trade was a 0.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Austin Aerts also recently made the following trade(s):

• On Monday, November 11th, Austin Aerts sold 7,179 shares of Sera Prognostics stock. The stock was sold at an average price of $7.32, for a total transaction of $52,550.28.

Sera Prognostics Price Performance

NASDAQ SERA opened at $6.61 on Thursday. Sera Prognostics, Inc. has a 1-year low of $4.98 and a 1-year high of $12.35. The stock has a market capitalization of $223.23 million, a price-to-earnings ratio of -6.68 and a beta of 0.86. The business’s fifty day moving average price is $7.44 and its 200-day moving average price is $7.31.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.09 million. During the same quarter last year, the firm earned ($0.23) earnings per share. Equities research analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Institutional Trading of Sera Prognostics

Large investors have recently added to or reduced their stakes in the business. Sanders Morris Harris LLC boosted its stake in shares of Sera Prognostics by 165.7% during the 4th quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company’s stock worth $725,000 after acquiring an additional 56,500 shares during the last quarter. Pallas Capital Advisors LLC bought a new position in Sera Prognostics in the 4th quarter worth $113,000. JPMorgan Chase & Co. grew its holdings in Sera Prognostics by 7,357.8% during the third quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock valued at $6,902,000 after purchasing an additional 873,002 shares during the period. Barclays PLC grew its holdings in Sera Prognostics by 321.6% during the third quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after purchasing an additional 30,093 shares during the period. Finally, Geode Capital Management LLC increased its position in Sera Prognostics by 8.9% in the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after buying an additional 47,969 shares in the last quarter. 54.64% of the stock is currently owned by institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.